Intravenous Busulfan Pharmacokinetics in Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Dosing Weight

被引：0
|
作者：
Bradley, Amber M. [1 ,2 ]
Evans, Sarah [2 ]
DeRemer, David [1 ,2 ]
Awan, Farrukh Tauseef [3 ]
机构：
[1] Georgia Hlth Sci Med Ctr, Augusta, GA USA
[2] Univ Georgia, Coll Pharm, Augusta, GA USA
[3] Georgia Hlth Sci Univ, Augusta, GA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2012.11.605
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
540
引用
收藏
页码：S373 / S374
页数：2
相关论文
共 50 条
  • [41] Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation:: Study of pharmacokinetics and early clinical outcomes
    Russell, JA
    Tran, HT
    Quinlan, D
    Chaudhry, A
    Duggan, P
    Brown, C
    Stewart, D
    Ruether, JD
    Morris, D
    Glück, S
    Gyonyor, E
    Andersson, BS
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (09) : 468 - 476
  • [42] Thiotepa-based conditioning regimens in allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis
    Dulery, R.
    Giannotti, F.
    Battipaglia, G.
    Ruggeri, A.
    Brissot, E.
    Malard, F.
    Sestili, S.
    Belhocine, R.
    Vekhoff, A.
    Gueye, M. S.
    Lapusan, S.
    Adaeva, R.
    Isnard, F.
    Legrand, O.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S337 - S337
  • [43] Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis
    Shouval, Roni
    Vega, Yakov
    Fein, Joshua A.
    Danylesko, Ivetta
    Tov, Noga Shem
    Yerushalmi, Ronit
    Sobas, Marta
    Czyz, Anna
    Nagler, Arnon
    Shimoni, Avichai
    BONE MARROW TRANSPLANTATION, 2020, 55 (01) : 147 - 156
  • [44] Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis
    Roni Shouval
    Yakov Vega
    Joshua A. Fein
    Ivetta Danylesko
    Noga Shem Tov
    Ronit Yerushalmi
    Marta Sobas
    Anna Czyż
    Arnon Nagler
    Avichai Shimoni
    Bone Marrow Transplantation, 2020, 55 : 147 - 156
  • [45] Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning
    Zao, Jamie H.
    Schechter, Tal
    Liu, Wenchao Jessica
    Gerges, Sandra
    Gassas, Adam
    Egeler, R. Maarten
    Grunebaum, Eyal
    Dupuis, L. Lee
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (08) : 1471 - 1478
  • [46] Impact of age on outcome after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with Fludarabine/Busulfan
    Bethge, W. A.
    Federmann, B.
    Helwig, A.
    Faul, C.
    Vogel, W.
    Kanz, L.
    ONKOLOGIE, 2012, 35 : 129 - 129
  • [47] Regimen related toxicity after thiotepa, cyclophosphamide and intravenous busulfan as conditioning for allogeneic stem cell transplantation
    Sanz, J
    Sanz, GF
    Moscardó, F
    Cupelli, L
    Montesinos, P
    Puig, N
    Lorenzo, I
    Benlloch, L
    Jarque, I
    de la Rubia, J
    Martínez, J
    Martín, G
    Sanz, MA
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 33 - 34
  • [48] Intravenous busulfan as part of conditioning regimen in children undergoing allogeneic and autologous haematopoietic stem cell transplantation
    Gomez-Garcia, L.
    Molina, J. R.
    Rodriguez, G.
    Rodriguez-Villa, A.
    Garcia, E.
    Buenasmananas, D.
    Llamas, M. J.
    Chic, C.
    Rojas, R.
    Carmen, M.
    Gomez, P.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S265 - S265
  • [49] Pharmacokinetics (PK) and toxicity of once daily dosing of intravenous busulfan (IVBU) in a reduced intensity preparative regimen for allogeneic stem cell transplantation (ASCT).
    Shaughnessy, PJ
    Tran, HT
    Andersson, B
    Sprigg-Saenz, H
    Ririe, D
    Ornstein, D
    Bachier, C
    LeMaistre, CF
    BLOOD, 2001, 98 (11) : 320B - 321B
  • [50] Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation
    Shimomura, Yoshimitsu
    Hara, Masahiko
    Yamamoto, Hisashi
    Ichinohe, Tatsuo
    Fukuda, Takahiro
    Takanashi, Minoko
    Atsuta, Yoshiko
    Ishikawa, Takayuki
    BLOOD, 2019, 134
12345